SCHEMBL8296597

SCHEMBL8296597

O=C(O)c1cc(Cl)ccc1OCCOC1CCCCO1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
TSHR P16473 2/20 0.46
GAA P10253 1/20 0.46
PTGDR2 Q9Y5Y4 5/20 0.44
HSD17B10 Q99714 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 2/20 0.42
ALDH1A1 P00352 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
PTGDR Q13258 3/20 0.41
CREBBP Q92793 1/20 0.41
PTGER2 P43116 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
PTGER1 P34995 2/20 0.39
DPP4 P27487 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8296601 0.91 MEN1 (0.54) MEN1KMT2ATSHRPTGDR2HSD17B10
SCHEMBL14614862 0.89 MEN1 (0.44) MEN1KMT2ATSHRPTGDR2HSD17B10
SCHEMBL8297703 0.88 NPC1 (0.44) MEN1KMT2ATSHRPTGDR2HPGD
SCHEMBL8303231 0.86 MEN1 (0.51) MEN1KMT2APTGDR2KDM4EALDH1A1
SCHEMBL871773 0.83 KMT2A (0.55) MEN1KMT2AKDM4EALDH1A1CREBBP
SCHEMBL8301772 0.82 MEN1 (0.47) MEN1KMT2ATSHRPTGDR2HSD17B10
SCHEMBL21818634 0.82 KMT2A (0.51) MEN1KMT2ATSHRKDM4EHPGD
SCHEMBL8297695 0.81 MEN1 (0.46) MEN1KMT2APTGDR2HPGDALDH1A1
SCHEMBL19175392 0.81 KDM4C (0.43) MEN1KMT2APTGDR2KDM4EHPGD
SCHEMBL8297007 0.80 MEN1 (0.54) MEN1KMT2ATSHRPTGDR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035313-A1 Compounds PFIZER INC. 2009-02-05 US disclosed
US-20090035313-A1 Compounds PFIZER INC. 2009-02-05 US disclosed
EP-1651641-B1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LTD (GB) 2007-05-23 EP disclosed
WO-2005009995-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed
WO-2005009965-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035313-A1 Compounds NQO1, NAMPT, NNT MEN1 532/4885KMT2A 2721/4885TSHR 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.